(1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol, identified by CAS 1006376-60-8, stands out as a highly valuable chiral intermediate in the pharmaceutical sector. Its significance is primarily tied to its indispensable role in the synthesis of Ticagrelor, a potent and reversible oral P2Y12 receptor antagonist used to prevent thrombotic events in patients with acute coronary syndrome. For pharmaceutical manufacturers and researchers, understanding the properties and sourcing of this intermediate is paramount.

The molecular structure of (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol features a difluorinated phenyl ring and a chiral alcohol group adjacent to a chloromethyl moiety. These structural elements are critical for its reactivity and suitability as a building block in complex organic synthesis. The specific stereochemistry at the chiral center (1S) is crucial, as it directly influences the biological activity of the final API, Ticagrelor.

When considering the purchase of this pharmaceutical intermediate, it is essential to work with reputable manufacturers and suppliers. A reliable supplier will offer the compound with high chemical and enantiomeric purity, backed by comprehensive Certificates of Analysis (CoA). These documents typically include details on molecular weight (192.59 g/mol), formula (C8H7ClF2O), purity levels, and results from analytical techniques such as NMR and HPLC. Such transparency from a China-based manufacturer can assure procurement managers of the material's quality and suitability for their intended use.

The synthesis of APIs like Ticagrelor often requires multiple steps, and the efficiency and yield of each step are heavily dependent on the quality of the intermediates used. Therefore, procurement teams must prioritize sourcing from manufacturers who demonstrate robust quality control processes and stable production capabilities. Inquiring about supply chain reliability, lead times, and bulk pricing for intermediates like (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol is a standard practice for any serious pharmaceutical R&D or production facility.

Moreover, the pharmaceutical industry is highly regulated. Working with suppliers who understand and adhere to these regulations, and can provide necessary documentation for regulatory submissions, is a significant advantage. For companies looking to buy (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol, partnering with an experienced manufacturer ensures not only the availability of a critical intermediate but also contributes to the overall success and compliance of their pharmaceutical development pipeline.